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Abstract 
Background: Expanded malaria control efforts in Sénégal have resulted in increased use of rapid diagnostic tests 
(RDT) to identify the primary disease-causing Plasmodium species, Plasmodium falciparum. However, the type of 
RDT utilized in Sénégal does not detect other malaria-causing species such as Plasmodium ovale spp., Plasmodium 
malariae, or Plasmodium vivax. Consequently, there is a lack of information about the frequency and types of malaria 
infections occurring in Sénégal. This study set out to better determine whether species other than P. falciparum were 
evident among patients evaluated for possible malaria infection in Kédougou, Sénégal.
Methods: Real-time polymerase chain reaction speciation assays for P. vivax, P. ovale spp., and P. malariae were devel-
oped and validated by sequencing and DNA extracted from 475 Plasmodium falciparum-specific HRP2-based RDT 
collected between 2013 and 2014 from a facility-based sample of symptomatic patients from two health clinics in 
Kédougou, a hyper-endemic region in southeastern Sénégal, were analysed.
Results: Plasmodium malariae (n = 3) and P. ovale wallikeri (n = 2) were observed as co-infections with P. falciparum 
among patients with positive RDT results (n = 187), including one patient positive for all three species. Among 288 
negative RDT samples, samples positive for P. falciparum (n = 24), P. ovale curtisi (n = 3), P. ovale wallikeri (n = 1), and P. 
malariae (n = 3) were identified, corresponding to a non-falciparum positivity rate of 2.5%.
Conclusions: These findings emphasize the limitations of the RDT used for malaria diagnosis and demonstrate that 
non-P. falciparum malaria infections occur in Sénégal. Current RDT used for routine clinical diagnosis do not neces-
sarily provide an accurate reflection of malaria transmission in Kédougou, Sénégal, and more sensitive and specific 
methods are required for diagnosis and patient care, as well as surveillance and elimination activities. These findings 
have implications for other malaria endemic settings where species besides P. falciparum may be transmitted and 
overlooked by control or elimination activities.
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Background
Among Plasmodium species that infect humans, Plasmo-
dium falciparum and Plasmodium vivax are responsible 
for most of the global mortality and morbidity. However, 
with intensified efforts to control the incidence of these 
primary species, there is rising concern over the preva-
lence of additional malaria species including Plasmodium 
ovale spp. and Plasmodium malariae into the niches 
previously occupied by P. falciparum and P. vivax [1–3]. 
Should these other species be undetected by current 
diagnostic methods, there is the potential that they may 
make substantive and possibly increasing contributions 
to overall malaria burden.
Globally, there have been sporadic reports of chang-
ing trends in the prevalence of malaria species other 
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than P. falciparum. For example, there are increasing 
reports of P. ovale spp. in various countries across the 
African continent, including Ethiopia, Uganda, Equato-
rial Guinea, and Kenya [1–3]. Historically, and recently, 
there have been ad hoc reports of malaria infections 
caused by species other than P. falciparum in Sénégal. 
While previous reports in Sénégal have indicated low 
or reduced incidence of these species [4, 5], there are 
limited data from other regions of the country, and it 
remains unknown if these observations can be general-
ized nationwide. Furthermore, P. malariae is relatively 
under-reported in these regions [6]. Recently, mul-
tiple clinical cases of P. vivax infection were detected 
in Sénégal [7]. However, it remains unclear if the pau-
city of data describing other malaria species is due to 
a lack of inadequate diagnostics or a consequence of 
relative lack of transmission in these regions. Overall 
there is insufficient information about the prevalence 
or dynamics of these malaria species, especially in the 
context of recent efforts to reduce or eliminate malaria. 
Moreover, no recent attempt has been made to system-
atically determine the prevalence of non-falciparum 
malaria parasites in Sénégal.
The region of Kédougou in southeastern Sénégal is an 
area of high malaria transmission that borders the coun-
tries of Mali and Guinea. It is characterized by relatively 
high humidity and an ecology that supports seasonal 
malaria transmission, with entomological inoculation rates 
between 100 and 200 and incidence rates of greater than 25 
per 1000 individuals [8–10]. Human migration to and from 
the region is encouraged by ongoing mining activities in 
Kédougou that have expanded in the most recent decade.
In addition to using previously-reported methods, this 
study also developed and validated a set of real-time PCR 
speciation assays to detect P. ovale spp., P. malariae, and 
P. vivax. These assays were applied to analyse nearly 500 
rapid diagnostic tests (RDT) from two health centers in 
Kédougou, Sénégal in order to assess the prevalence of 
non-falciparum species in this region.
Methods
Sample collection site
Kédougou (12°56′00″ N, 12º21,00″W) is situated in 
the extreme southeastern part of Sénégal, in a tropical 
savanna located 710  km from Dakar, the nation’s capi-
tal (Fig.  1). Its 151,715 inhabitants comprise around 5% 
Dakar
Malaria Incidence per 1,000 Individuals by Health District, 2013
Fig. 1 Study area. Map of Sénégal showing the location of health clinics in Kédougou relative to Dakar. Shading indicates malaria incidence levels. 
Figure adapted from the National Strategic Framework 2014–2018 [10]
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of the national population. The passive case detection 
in this study was based on patients aged 6  months or 
older reporting to health clinics in Tomboronkonto and 
Dindefelo for suspected malaria with fever or history of 
fever in the previous 48 h. Samples were collected from 
the first patient over 5  years of age as well as the first 
patient under 5  years of age reporting daily, for 4  days 
of the week over the course of a single year, a sampling 
scheme considered roughly representative of the sympto-
matic population reporting to health care facilities. These 
patients were diagnosed by RDT (First Response Malaria 
Ag [HRP2], Premier Medical Corp., USA), and parasite 
material from these discarded RDT was extracted for 
species identification. Institutional Review Board (IRB) 
review of these discarded diagnostic materials that were 
anonymous and de-identified were deemed non-human 
subjects material and used accordingly.
Sample type and extraction
Parasite DNA was isolated from the filter pad of the RDT 
using the Promega DNA IQ Casework Pro Kit for Max-
well 16 (Promega Corp., Madison, WI, USA) as directed 
by the manufacturer.
Speciation assays
First, species-specific TaqMan real-time assays were 
developed to target the Plasmodium plasmepsin 4 
gene based on previously-reported sequence data [11] 
(Table  1). Each DNA sample was run in duplicate with 
plasmid-based standard curves from 50,000 to 0.5 cop-
ies. The control plasmids contained species-specific 
plasmepsin 4 genes (Genbank accession numbers 
AF001208.1, AF001209.1, and 144 AF001210.1 for P. 
vivax, P. ovale spp., and P. malariae, respectively).
Next, each extracted RDT sample was pre-amplified 
[12] with species-specific primers (Table  1). The P. fal-
ciparum primers targeted the PF3D7_0718800 gene, as 
described previously [13].
Briefly, each reaction was performed with 3 µL of pre-
amplified parasite DNA in a 15 µL total reaction volume 
(2×  qPCR Master Mix, 20× primer-probe mix, and 
PCR-grade water). Amplification and detection were per-
formed under the following conditions: 15-min incuba-
tion at 37  °C prior to amplification, initial denaturation 
for 15  min at 95  °C, then 40 cycles of denaturation for 
10 s at 95 °C, and 1 min at 60 °C with data collection.
The specificities of the P. malariae, P. vivax, and P. ovale 
spp. real-time assays were validated by Sanger sequenc-
ing (Macrogen Corp., Rockville, MD) of the amplicon 
products, both from the synthesized plasmids and the 
amplification-positive samples identified in the current 
study.
Plasmodium ovale follow‑up
Plasmodium ovale curtisi and Plasmodium ovale wallik-
eri were identified among P. ovale–positive samples using 
PoTRA3 and PoTRA5 primers in a nested PCR amplifi-
cation of the tryptophan rich repeat region as described 
previously [10]. The PCR mixture consisted of 5  µL 
of DNA in a final volume of 20 µL (6 µL Phusion high-
fidelity master mix [New England Biolabs, Ipswich, MA, 
USA], 2 µL of 10 pmol each forward and reverse primer, 
Table 1 Primer and probe sequences
Gene Primer name Primer sequence (5′– >3′) Amplicon size (bp) Specificity Reference
Porbp2 Porbp2TMfwd TTGCAAACAAAAGTGCTCC 120 P. ovale [2]
Porbp2TMrev CCTAATTCTCTTTGT(G/A)CCC
Potra PoTRA fwd3 GCACAAAAATGGTGCTAACC 787 P. ovale [2]
PoTRA rev3 ATCCATTTACCTTCCATTGC
PoTRA fwd5 ACGGCAAACCCGATAAACAC 245–355
PoTRA rev5 GTGTTTGTAGTATTTACAGG
Plasmepsin 4 AIRSAMA_Fwd ACTGACACTGATGATTTAGAACCCATTT 1353 P. vivax
AIRSAMA_Rev TGGAGAGATCTTTCCATCCTAAACCT
AIRSAMA_Probe CAGCAGCGTCGAGTTT
Plasmepsin 4 Ovale_CCRR9V5_Fwd ACTCTTGGTTATTTGTCTGCACCTT 1353 P. ovale
Ovale_CCRR9V5_Rev CTATGTTACCATAAACAGGTTCTAAATCATCTGT
Ovale_CCRR9V5_Probe TCAGTTGCTTCAACAAATTT
PF3D7_0718800 pf07_0076_Fwd CGACCCTGATGTTGTTGTTGGA 79 P. falciparum [11]
pf07_0076_Rev GGCTTTTTTCCATTTCTGTAGTTAAGATTCA
pf07_0076_Probe CAACAGCTCCAAAATAT
Plasmepsin 4 Malariae_CCWR2K1_Fwd TTCAGTCAGGATATGTAAAACAAAATTATTTAGGTAGT 1356 P. malariae
Malariae_CCWR2K1_Rev CCTACTTCCCCTTCACCATAAAACA
Malariae_CCWR2K1_Probe TCGTCTAGTTCTATTACGTCATTTTC
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and 5 µL PCR-grade water). Infections with P. ovale wal-
likeri yielded a product of 245  bp, and P. ovale curtisi a 
317 bp product.
DNA sequences at loci of interest were determined 
by direct sequencing of the final PCR product using 
PoTRA5 primers (Table  1). Sequences are available as 
GenBank accession numbers KX417699–KX417705.
High‑resolution melting assays
Samples positive for P. ovale were additionally tested by 
high-resolution melting to differentiate sub-species using 
the porbp2 primers, as described previously [2].
Results
Validation of plasmepsin 4 P. ovale spp., P. malariae, and P. 
vivax assays
Amplicon products of these assays using control DNA 
templates and plasmid controls were confirmed to match 
sequences deposited to GenBank with 100% sequence 
concordance.
Overall RDT performance
A total of 475 HRP2-based RDT collected in Kédougou 
by the Programme National de Lutte contre le Paludisme 
(National Malaria Control Programme or PNLP) were 
evaluated in this study (Fig. 2). Of these, 187 were positive 
for P. falciparum (RDT positivity rate: 39.3%, 187 of 475 
samples). Furthermore, among the 288 samples negative 
for P. falciparum by RDT, 24 were positive for amplifica-
tion of the P. falciparum PF3D7_0718800 gene (Additional 
file  1: Figure S1), indicating the presence of this species 
even in RDT-negative samples (PCR positivity rate: 44.4%, 
211 of 475 samples). The detection of Plasmodium showed 
similar trends between the two clinic settings (Tombo-
ronkonto and Dindefelo, Additional file 2: Figure S2).
Evidence of malaria species other than Plasmodium 
falciparum among samples collected by passive case 
detection in Kédougou, Sénégal
Analysis of the RDT-positive samples revealed co-infec-
tion of P. falciparum with P. malariae (n  =  3) and P. 
ovale (n = 2); with one sample positive for all three spe-
cies. Both P. ovale (n = 4) and P. malariae (n = 3) were 
identified from among the 288 RDT-negative samples 
(Table 1). Although previous reports [7] indicate P. vivax 
infections in this region, in this study population there 
were no samples positive for P. vivax.
Sympatric circulation of Plasmodium ovale wallikeri 
and Plasmodium ovale curtisi
To further distinguish between the known subtypes of P. 
ovale infection, we employed a high-resolution melting 
analysis approach and confirmed that two of the RDT-
positive samples were positive for P. ovale wallikeri; of 











































Fig. 2 Flow chart of patient samples and species analysis
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four RDT-negative samples, three and one were posi-
tive for P. ovale curtisi and P. ovale wallikeri, respectively 
(Figs.  3, 4). These data indicate that both subtypes of P. 
ovale are evident in the southeastern part of Sénégal.
To confirm the sensitivity and specificity of the geno-
typing results for P. malariae and P. ovale, we used a 
sequencing approach. Sanger sequencing of the positive 
samples was used to confirm the presence of P. malariae 
and P. ovale among the samples, and a BLAST search of 
the resultant sequences showed high identity with previ-
ously reported sequences. Sequencing was also able to dis-
tinguish between the P. ovale curtisi and P. ovale wallikeri 
identified in these samples; the sequencing results were 
concordant with those of the high-resolution melt findings.
Discussion
After significant restructuring in 2005, the Programme 
National de Lutte contre le Paludisme (PNLP) in Séné-
gal developed a control strategy implemented between 
2006 and 2010 that involved distribution of RDT to all 
health facilities (2007), nationwide access to artemisinin 
combination therapies (2007 and 2008), and distribu-
tion of insecticide-treated bed nets (2007–2009). While 
the initial results of this strategy were encouraging based 
on the nationwide reported incidence of P. falciparum, 
several regions have experienced malaria rebound since 
2009 [14]. Of concern is that HRP2-based surveillance 
may miss both non-P. falciparum malaria species as well 
as low-density P. falciparum infections and infections 
composed exclusively of P. falciparum parasites that lack 
HRP2 and HRP3 expression [15].
The PNLP has also conducted nationwide cross-sec-
tional surveys for disease surveillance. Kédougou, in 
southeastern Sénégal, is a region that borders Mali and 
Guinea with relatively high transmission, as indicated 
by entomological inoculation rates (EIRs) of 100–200 
[9, 10]. Recent reports have identified P. vivax malaria in 
Kédougou [7]. Although P. vivax was not observed in the 
population assessed in the current study, P. ovale wallik-
eri, P. ovale curtisi, and P. malariae were identified, none 
of which are tested for by the current RDT. It remains to 
be determined if this incidence is changing, particularly 
in comparison with reduced P. falciparum transmission 
in response to increased eradication efforts that target 
P. falciparum vectors and their characteristic behaviors, 
which might not be common in other Plasmodium spe-
cies. Indeed, there is evidence of significant biological 
differences between P. ovale spp. and P. falciparum, with 
increased latency times reported in patients infected with 
the former and differences in clinical features between P. 
ovale curtisi and P. ovale wallikeri [16]. Additional studies 
Fig. 3 Summary of sample species positivity by rapid diagnostic 
test status. Shaded boxes indicate samples positive for the respective 
Plasmodium species based upon the PCR-based testing described
Fig. 4 High-resolution melting differentiation of P. ovale curtisi and P. ovale wallikeri
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are necessary to more fully characterize the nationwide 
prevalence of these non-falciparum species; to iden-
tify their source as importation or local transmission; 
their primary transmission vectors; and to differentiate 
between relapse, reinfection, or recrudescence events 
where applicable.
The results of this study underscore the potential lim-
itations of the routine use of standard RDT for malaria 
detection in Sénégal both in terms of missing P. falci-
parum infections as well as missing non-P. falciparum 
malaria infections in Kédougou, Sénégal. The current 
RDT likely detects most of the infections in this region, 
particularly those without co-infections; however, while 
the relative proportion of non-falciparum infections 
remains low, it may increase with improved patient 
access to diagnosis and treatment. Furthermore, the find-
ings of the current study, including the presence of P. fal-
ciparum genetic material in RDT-negative samples and 
subsequent differences in positivity rates (39.3 vs. 44.4%), 
are similar to those of previous reports [17] that PCR-
based detection of parasites genomic material is more 
sensitive than standard RDT. This suggests the need for 
more sensitive methods to detect infections, particularly 
in asymptomatic patients and in the context of declin-
ing transmission and malaria incidence rates. This study 
developed tools that allow for the sensitive identification 
of these infections for surveillance of the incidences of 
infection and their changes in response to control efforts.
The lack of detection of P. falciparum may be due to 
either low parasite densities, below the level of detec-
tion of the RDT or lack of specific HRP2 loci in the 
parasite population that results in a negative diagnostic 
test. Reports of non-falciparum malaria are of concern 
with control and elimination efforts that increasingly 
rely on HRP2-based and P. falciparum-specific RDT, as 
these may miss infections that contribute to continued 
malaria transmission, and thus may undermine elimina-
tion efforts and impact morbidity and mortality due to 
malaria. Failure to detect malaria infections other than P. 
falciparum is most likely is due to the specificity of the 
RDT, which was not designed to detect these malaria 
species. Regardless of the specific reasons why the RDT 
failed to detect these infections, these findings point to 
the need for appropriate diagnosis and surveillance of 
malaria infection to provide both adequate clinical treat-
ment and to direct elimination strategies to address the 
nature of ongoing malaria infection in a given endemic 
setting. Future studies are necessary to assess and track 
the prevalence of HRP2 deletions in endemic populations 
in this region.
This study has several limitations. First, the pre-
amplification step, like nested and multi-step PCR 
reactions, offers increased sensitivity to detect para-
sites at low concentrations, but prevents us from 
determining the threshold cycles (Ct) values of the 
original samples; furthermore, RDT were administered 
by regular health care providers rather than staff spe-
cifically trained for malaria testing. Blood smears were 
not obtained from the patients, and trained micros-
copists were not available; therefore, parasite densi-
ties in these patients were not determined. Finally, the 
sampling scheme was not a cross-sectional study, so 
there is a potential bias in the study population. Future 
cross-sectional studies including larger sample sizes 
and asymptomatic patients are necessary to validate 
these findings.
Despite these limitations, the findings of this study sug-
gest the importance of assessing the true prevalence of 
specific malaria infections using appropriate diagnostic 
methods to evaluate the requirements for health care ser-
vices and develop appropriate strategies for malaria elim-
ination. Such quantification is increasingly important in 
order for malaria elimination programmes to implement 
species-appropriate detection, prevention, and treatment 
strategies.
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